<div id="readability-page-1"><p>Asset Management One Co. Ltd. grew its stake in shares of  Abbott Laboratories (NYSE:ABT - Free Report) by 8.4% in the 4th quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 781,611 shares of the healthcare product maker's stock after buying an additional 60,871 shares during the period. Asset Management One Co. Ltd.'s holdings in Abbott Laboratories were worth $89,877,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Abbott Laboratories</strong> alerts:</span></p></div><ul><li>Abbott Laboratories Will Outperform Healthcare Stocks in 2025</li></ul><p>Other institutional investors and hedge funds have also made changes to their positions in the company. Insight Folios Inc increased its stake in  Abbott Laboratories by 3.3% during the third quarter. Insight Folios Inc now owns 2,691 shares of the healthcare product maker's stock worth $307,000 after acquiring an additional 87 shares during the last quarter.  Sfmg LLC raised its holdings in  Abbott Laboratories by 1.9% in the third quarter. Sfmg LLC now owns 4,622 shares of the healthcare product maker's stock valued at $527,000 after buying an additional 88 shares during the period.  River Street Advisors LLC lifted its position in  Abbott Laboratories by 1.2% during the fourth quarter. River Street Advisors LLC now owns 7,370 shares of the healthcare product maker's stock valued at $834,000 after buying an additional 88 shares in the last quarter.  Wedge Capital Management L L P NC grew its stake in  Abbott Laboratories by 2.9% during the third quarter. Wedge Capital Management L L P NC now owns 3,153 shares of the healthcare product maker's stock worth $359,000 after buying an additional 89 shares during the period.  Finally, Silicon Valley Capital Partners raised its stake in shares of  Abbott Laboratories by 8.7% in the 3rd quarter. Silicon Valley Capital Partners now owns 1,108 shares of the healthcare product maker's stock valued at $126,000 after acquiring an additional 89 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Insider Buying and Selling</h2><p>In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at approximately $16,152,064.50. This trade represents a 15.90 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Corporate insiders own  1.10% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>These Are The Top Health Stocks to Own for Buy-and-Hold Investing</li></ul><p>A number of analysts recently weighed in on ABT shares. Piper Sandler upped their price target on shares of Abbott Laboratories from $131.00 to $133.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, October 17th. StockNews.com lowered Abbott Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Wednesday. Barclays  restated an &#34;overweight&#34; rating and issued a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a report on Monday, January 27th. Mizuho lifted their price objective on shares of Abbott Laboratories from $115.00 to $130.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, October 17th. Finally, Stifel Nicolaus upped their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, fourteen have issued  a buy rating and one  has issued  a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $133.06.</p><p><b>View Our Latest Report on ABT</b></p><h2>Abbott Laboratories Stock Performance</h2><ul><li>MarketBeat Week in Review – 10/14 - 10/18</li></ul><p>ABT stock opened at $131.83 on Friday. The firm has a market cap of $228.66 billion, a P/E ratio of 17.23, a P/E/G ratio of 2.39 and a beta of 0.75. The stock's 50 day simple moving average is $118.34 and its 200 day simple moving average is $115.71. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $132.50. </p><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11.03 billion. During the same quarter in the previous year, the firm posted $1.19 EPS. The business's revenue for the quarter was up 7.2% compared to the same quarter last year.  As a group, equities research analysts predict that  Abbott Laboratories will post 5.14 EPS for the current year. </p><h2>Abbott Laboratories Increases Dividend</h2><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.79%. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories's dividend payout ratio (DPR) is 30.85%. </p><h2>Abbott Laboratories Profile</h2> (Free Report)<p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Abbott Laboratories</li><li>What Are Growth Stocks and Investing in Them </li><li>Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up</li><li>How to Invest in the FAANG Stocks</li><li>Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?</li><li>What is the Australian Securities Exchange (ASX) </li><li>Buffett Buys More Occidental Petroleum—Sticking to His Playbook</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Where Should You Invest $1,000 Right Now?</h2><p>Before you make your next trade, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.</p><p>Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.</p><p>They believe these five stocks are the five best companies for investors to buy now...</p><p>See The Five Stocks Here </p><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2><p>Before you consider Abbott Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p><p>While Abbott Laboratories currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Asset Management One Co. Ltd. increased its stake in Abbott Laboratories (NYSE:ABT) by 8.4% in Q4, owning 781,611 shares valued at $89.88 million. Other institutional investors also adjusted their positions. EVP Daniel Gesua Sive Salvadori sold 23,771 shares, reducing his stake by 15.90%. Analysts have mixed ratings on ABT, with an average target price of $133.06. The stock opened at $131.83, with a market cap of $228.66 billion and a P/E ratio of 17.23.</p>

Abbott Laboratories (NYSE:ABT) Shares Purchased by Asset Management One Co. Ltd.